Direkt zum Inhalt
Merck
  • Synthesis and biological evaluation of L-cysteine derivatives as mitotic kinesin Eg5 inhibitors.

Synthesis and biological evaluation of L-cysteine derivatives as mitotic kinesin Eg5 inhibitors.

Bioorganic & medicinal chemistry letters (2007-05-26)
Naohisa Ogo, Shinya Oishi, Kenji Matsuno, Jun-ichi Sawada, Nobutaka Fujii, Akira Asai
ZUSAMMENFASSUNG

Inhibition of Eg5 represents a novel approach for the treatment of cancer. Here, we report the synthesis and structure-activity relationship of S-trityl-L-cysteine (STLC) derivatives as Eg5 inhibitors. Some of these derivatives such as 4f demonstrated enhanced inhibitory activity against Eg5 and induced mitotic arrest with characteristic monoastral spindles in HeLa cells.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
L-Cystein, 97%
Sigma-Aldrich
L-Cystein, from non-animal source, BioReagent, suitable for cell culture, ≥98%
Sigma-Aldrich
L-Cystein, BioUltra, ≥98.5% (RT)
SAFC
L-Cystein
Sigma-Aldrich
L-Cystein, ≥97%, FG
Sigma-Aldrich
S-Methyl-L-Cystein, substrate for methionine sulfoxide reductase A
Sigma-Aldrich
Fmoc-Cys(Trt)-OH, ≥95.0% (sum of enantiomers, HPLC)
Sigma-Aldrich
S-Carboxymethyl-L-Cystein
Sigma-Aldrich
Boc-Cys(Trt)-OH, 97%
Sigma-Aldrich
S-Benzyl-L-Cystein, 97%